Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
暂无分享,去创建一个
J. Pignon | T. Conroy | M. Ychou | P. Rougier | P. Lasser | V. Boige | O. Bouché | L. Bedenne | J. Fabre | M. Ducourtieux | J. Genève | B. Saint-Aubert | G. Lebreton | B. Saint‐Aubert
[1] P. Schlag,et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] E. Steyerberg,et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. , 2010 .
[3] Yasuo Ohashi,et al. Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer , 2009 .
[4] D. Cunningham,et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2010, The New England journal of medicine.
[5] A. Taghian,et al. Prognostic factors for local control after breast conservation: does margin status still matter? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] W. Allum,et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Ajani,et al. Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Stuschke,et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Hofheinz,et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] E. Maillard,et al. Individual Patient Data-based Meta-analysis Assessing the Effect of Preoperative Chemo-radiotherapy in Resectable Oesophageal Carcinoma , 2008 .
[11] J. Ajani,et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. L. Maître,et al. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma , 2007 .
[13] Val Gebski,et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. , 2007, The Lancet. Oncology.
[14] D. Rattner,et al. Management of gastroesophageal tumors. , 2007, The oncologist.
[15] L. Schwartz,et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Ajani,et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] F. J. Ramos,et al. Novel targets in gastric and esophageal cancer. , 2006, Critical reviews in oncology/hematology.
[18] C. V. D. van de Velde,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.
[19] J. Ajani,et al. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer : A Report of the V 325 Study Group , 2006 .
[20] T. Hickish,et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF , 2005, British Journal of Cancer.
[21] A. Livingstone,et al. Neoadjuvant Treatment for Resectable Cancer of the Esophagus and the Gastroesophageal Junction: A Meta-Analysis of Randomized Clinical Trials , 2003, Annals of Surgical Oncology.
[22] D. Girling. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial , 2002, The Lancet.
[23] T. Muto,et al. [Neoadjuvant chemotherapy for advanced gastric cancer]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.
[24] L J Schouten,et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. , 2000, International journal of epidemiology.
[25] M. Pera. Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. , 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[26] J. Ajani,et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. , 1998, The New England journal of medicine.
[27] J. Fraumeni,et al. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States , 1998, Cancer.
[28] D. Stablein,et al. A partially grouped logrank test. , 1997, Statistics in medicine.
[29] A. Melcher,et al. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. , 1996, British Journal of Cancer.
[30] N. Mulder,et al. Neo-adjuvant chemotherapy with carboplatin, 4-epiadriamycin and teniposide (CET) in locally advanced cancer of the cardia and the lower oesophagus: a phase II study. , 1995, Anticancer research.
[31] J. Pignon,et al. Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. , 1994, European journal of cancer.
[32] Siewert,et al. Prognostic relevance of systematic lymph node dissection in gastric carcinoma , 1993, The British journal of surgery.
[33] D. Sleijfer,et al. Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: Phase II study with methotrexate and 5‐fluorouracil , 1991, The British journal of surgery.